Editorial Perspectives On Cell Line Development

  1. The “Liberation” Of Science Yields A New Class Of Biopharma Leadership 9/21/2022

    Purespring Therapeutics’ Richard Francis is among the dozens of big pharma executives who have defected to biopharma startups on the science, tech, and finance tides. “When I saw some of the acquisitions we were doing, it occurred to me that there’s no correlation between the places from which good science is emerging and a big R&D budget," he says.

  2. The Philogen Family Prepares For Market 9/6/2022

    In 1996, Prof. Dario Neri and his brothers Duccio and Giovanni founded the biopharma Philogen. Today, three of the company’s 17 clinical-stage programs are in phase 3 trials, seven in phase 2. Prof. Neri offered insight into the company’s academically rooted, metered approach on episode 103 of the Business of Biotech podcast.

  3. Why It's Computational Biology's Time To Shine 8/17/2022

    Astronomical biologic development costs, contracting capital markets, painfully long timelines, and an increasingly stingy regulatory environment are just a few of the reasons computational biology solutions are moving from the “luxury” column to the “survival” column for biopharmaceutical companies. 

  4. AAV Gene Therapy Takes On Kidney Disease 7/6/2022

    Built on the back of Prof. Moin Saleem’s two decades of cellular-level kidney research, Purespring Therapeutics is reimagining the treatment of kidney diseases that affect nearly a billion people worldwide. The company is preparing a first-of-its-kind AAV gene therapy candidate for the clinic. 

  5. The Coming Wave Of Radio(bio)pharmaceuticals 6/13/2022

    Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling technologies improve on previous failures, CEO, CMO, and co-founder Dr. Philip Kantoff is projecting a new wave of activity in the space among biopharmas big and small.

  6. Virtual Event: Overcome Platform Inefficiencies In mAb Manufacturing 6/7/2022

    Join multifaceted mAb manufacturing experts Gene Lee, CTO at AltruBio and Avril Vermunt, Sr. Director of Manufacturing Sciences & Technology at
    EQRx for a discussion on making mAbs more efficiently in the face of rising costs, growing complexity, and constricting cash runways. 

  7. IPSCs For Democratized Cell Therapy 6/7/2022

    Dr. Daniel Teper and his team at Cytovia Therapeutics have developed a unique combination of candidates designed to improve access to safe and affordable "off-the-shelf" cell therapies. Founded just four years ago, the company is preparing multiple clinical trials of IPSC-derived therapies, which Dr. Teper says lend to a consistent, scalable manufacturing process. 

  8. Will Anellovirus Vectors Solve Immunogenicity Challenges? 5/20/2022

    Ring Therapeutics is building a first-of-its-kind viral vector platform based on a commensal virus that flies under the immune system’s radar. If its odds-beating CEO is any indication of its success, the company just might beat the immunogenicity challenge.

  9. How To Build A Genomic Medicine Biotech 5/11/2022

    SparingVision CEO Stephane Boissel took the reins of a fledgling, single-asset gene therapy company born of academic research and quickly built a well-funded startup with a deepening pipeline of ocular disease candidates. He told the Business of Biotech how it happened.

  10. The CAR T Speed Show 5/9/2022

    Some mainstream, high-profile research out of the University of Pennsylvania has re-energized emerging cell therapy developers’ focus on manufacturing and administration speed. Speedy cell therapy pioneer EXUMA Biotech provides an update on its approach.